Hindustan Copper Regulatory Approval

Other Announcement

Hindustan Copper Other Announcement

Hindustan Copper Ltd submitted its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.

Management Change

Hindustan Copper Management Change

Shri Tarak Nath Nayak, General Manager (Engineering Services), has taken charge as Unit Head of the Taloja Copper Project and Gujarat Copper Project.

Management Change

Hindustan Copper Management Change

Hindustan Copper Limited has re-designated three senior management personnel, effective from their date of joining, on or before 09.10.2026.

Annual General Meeting

Hindustan Copper Annual General Meeting

Hindustan Copper Limited held its 59th Annual General Meeting on September 23, 2026, where shareholders approved financial statements, dividend declaration, director appointments, and fund-raising proposals.

Dividend

Hindustan Copper Dividend

Hindustan Copper shareholders approved FY25-26 dividend of ₹1.86 per share (37.20%) at the 59th AGM. Payment date is set for 16 October 2026.

Credit Rating

Hindustan Copper Credit Rating

ICRA upgraded Hindustan Copper's long-term rating to [ICRA]AAA (Stable) and reaffirmed its short-term rating at [ICRA]A1+ for bank facilities and commercial paper totaling ₹2,200 Crore.

Value

₹2,200 Cr

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.